Brofaromine
Brofaromine is a reversible inhibitor of monoamine oxidase A discovered by Ciba-Geigy. The compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market.
Brofaromine also acts as a serotonin reuptake inhibitor, and its dual pharmacologic effects offered promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with older standard drugs like the tricyclic antidepressants.Pharmacology
Brofaromine is a reversible inhibitor of monoamine oxidase A and acts on epinephrine, norepinephrine, serotonin, and dopamine. Unlike standard MAOIs, possible side effects do not include cardiovascular complications with encephalopathy, liver toxicity or hyperthermia.
